Catalog Advanced Search
-
Contains 15 Component(s)
SIG Presentations
This activity holds all Special Interest Group (SIG) presentations from The Liver Meeting 2023.
-
Contains 4 Product(s)
View on-demand presentations from The Liver Meeting® 2023. The Liver Meeting® is AASLD’s largest meeting covering a variety of trending topics.
This package will include:
- The Postgraduate Course: Cirrhosis As a Multisystem Disorder
- 2023 TLM Debrief Sessions
- State of the Art Programs
-
Contains 2 Component(s)
Moderators: Mary Thomson, MD; Kali Zhou, MD, MAS Speakers: Gia Landry, MD, Tatyana Kushner, MD, MSCE
During this webinar, the speakers will describe two unique populations and the practical aspects and health systems models needed to treat hepatitis C: pregnant and incarcerated people. The emerging data regarding safety and efficacy of treating hepatitis C during pregnancy will be discussed, as well as the effects on maternal to child transmission. There will also be discussion on the individual opportunities and challenges of treating hepatitis C in incarcerated people, as well as the downstream community effects of treating hepatitis C in this setting. Lastly, there will be an overview of the Louisiana Corrections Model, which is a successful example of using policy to overcome gaps in the corrections system.
Mary Thomson (Moderator)
Dr. Thomson is an Assistant Professor in the Division of Gastroenterology, Hepatology, and Nutrition at the University of Minnesota. Dr. Thomson’s clinical and research interests include health care delivery in cirrhosis and early identification of alcohol-related liver disease, particularly in women. She is on the AASLD Public Health SIG steering committee. She received an AASLD Transplant Hepatology Grant to fund her clinical research efforts.
Gia Landry, MD (Moderator)
Dr. Gia Landry is director of hepatology for The Liver Center Ochsner Baton Rouge and clinical assistant professor of medicine at Louisiana State University Health Science Center. She is the clinical expert for the Louisiana Department of Health’s initiative to eliminate hepatitis C (HCV). The HCV elimination initiative is one of the first of its kind in the United States, where a state is working toward eliminating hepatitis C as a public health threat. In this role she helps create training documents and provides training to primary providers around the state of Louisiana to treat hepatitis C, along with implementation and training within the Department of Corrections. She has published multiple peer reviewed articles on HCV elimination, hepatitis C, hepatitis B and hepatocellular carcinoma.
Tatyana Kushner, MD, MSCE
Dr. Kushner is an Associate Professor in the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai and holds a joint appointment in the Department of Obstetrics, Gynecology and Reproductive Sciences. Her research addresses understanding the epidemiology and outcomes in individuals living with viral hepatitis, particularly among individuals of childbearing age and pregnancy. She is a member of the AASLD/ IDSA HCV Guidance committee, a member of the Global NASH Council Viral Hepatitis Committee, and Chair of the AASLD Women's Initiative Committee. She is founder and director of the Mount Sinai Women’s Liver Clinic which is a clinic co-located on the Obstetrics Department and provides dedicated care to individuals living with viral hepatitis and other liver conditions during pregnancy and postpartum.
-
Contains 1 Component(s)
Hosted by the Portal Hypertension SIG
Moderators: Patrick Northup, MD, FAASLD
Speakers: Constantine Karvellas, MD, SM, FRCPC, FCCM, Brian Buchanan
-
Contains 5 Component(s)
Plenary Lectures from the Annual Meeting
3067: President's Choice State of the Art Lecture: Digitized Medicine
3069: Thomas E. Starzl Liver Transplant State of the Art Lecture: Alcohol-Associated Liver Disease: Transplant Triumphs and Challenges
3102: Hyman J. Zimmerman State of the Art: New Diagnostic Approaches in Acetaminophen Acute Liver Injury
3060: Leon Schiff State of the Art: Personalized Approach to HCC
-
Contains 7 Component(s)
11-14-2023
Speakers:
Rebecca Wells, MD: Basic Science Debrief
Juan Albraldes, MD: Portal Hypertension Debrief
Jennifer Price, MD, PhD: Hepatitis Debrief
Gideon Hirschfield, FRCP PhD: Cholestasis Debrief
Mazen Noureddin, MD, MHSc: MASLD Debrief
-
Contains 3 Product(s)
View on-demand presentations from The Liver Meeting® 2023.
View on-demand presentations from The Liver Meeting® 2023. The Liver Meeting® is AASLD’s largest meeting covering a variety of trending topics.
-
Contains 1 Component(s)
2024 Webinar
Hosted by: Inclusion and Diversity Committee
Moderator: Chimaobi Anugwom, MBBS
Speaker: Julius Wilder, MD, PhD; Lorna Dove, MD, MPH -
Contains 1 Component(s)
Hosted live on November 1, 2023 by the MASLD SIG.
The nomenclature change from nonalcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) marks a significant advancement in liver disease understanding as it recognizes the role of metabolic factors beyond fat accumulation in liver disease. The webinar will delve into the rationale and purpose of this shift in nomenclature in its ability to foster interdisciplinary collaboration, enhance public health initiatives, and drive focused research in the various phenotypes within steatotic liver diseases for improved patient outcomes. Embracing MASLD heralds a future of effective liver disease management including pharmacologic and non-pharmacologic intervention(s) and empowers healthcare professionals to better understand and manage the disease.
Our audience will gain a better understanding of the rationale behind the nomenclature change in steatotic liver disease classification, specifically on the evolving evidence and concepts in liver disease pathophysiology that necessitated the shift in nomenclature. Emphasis will be placed on the clinical application of the new classification, exploring how it enables more accurate diagnoses and tailored interventions for patients. Lastly, its potential implications for future research and pharmacologic development, showcasing its role in advancing the field and improving patient outcomes.
